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Background: Recent studies suggest that anti-diabetic medications which target the Glucagon-like Peptide 1 (GLP1) pathway (i.e. Dipeptydil 
Peptidase 4 inhibitors and GLP1 analogs [GLP1 agents]) may be protective in heart failure (HF). However, there are no large observational studies or 
randomized trials to support these preliminary findings.
methods: To further test this hypothesis, we performed a retrospective cohort study among members of a large health system in southeast 
Michigan. We identified more than 19,000 adult diabetic patients with an oral diabetes medication fill between January 1, 2000 and July 1, 2012. 
Patients initiating treatment with GLP1 agents were matched 1:2 to controls using propensity matching which accounted for age, race, gender, 
coronary disease, HF, duration of diabetes, and the number of antidiabetic medications. Multivariable Cox regression was used to test the effect of 
GLP1 agents on time to HF hospitalization. Secondary endpoints included all-cause hospitalization and all-cause mortality.
results: We identified 1,488 new users of GLP1 agents and 2,939 propensity matched controls. The groups were similar on all matched variables 
except the number of anti-diabetic medications (1.2 vs. 1.4, p<0.001) and age (60.4 vs. 61.7 years, p<0.001). Over a median observation time of 
663 days there were 281 hospitalizations, of which 184 were due to HF, and 158 deaths. Use of GLP1 agents was associated with reduced risk of HF 
hospitalization (adjusted hazard ratio [aHR] 0.56; 95% confidence interval [CI] 0.40-0.78, p<0.001), all-cause hospitalization (aHR 0.56; 95% CI 
0.42-0.73, p<0.001), and death (aHR 0.20; 95% CI 0.13-0.33, p=0.001).
conclusions: Our findings suggest that anti-diabetic agents which enhance GLP1 activity may have additional benefit of reducing the risk of HF 
events among diabetic patients. Additional studies are warranted to validate this association.
